ImmunityBio Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Right. Welcome, everyone, to Jefferies 2026 Global Healthcare Conference in London. My name is Roger Song, senior analyst, covers biotech in the U.S. It is my pleasure to have the next fireside chat with ImmunityBio CEO, Rich Adcock.
Welcome, Rich. Thank you. First of all, I'd just like to say thank you to the Jefferies team for inviting us and for everybody here being present in the audience.
Excellent. All right. Richard, why not you give us some overview of ImmunityBio, where you're coming from, what you're heading to, and why you're excited about the future, and particularly 2027, then we do have a lot of the specifics we can talk about today.
Sounds great. I think maybe one of the things to just, let's just jump right into is Q3, as we look at what's happening there on those. Before I start on any of those, I'll just start almost just exactly like the last one. We're not going to be providing any forward guidance for 2027 or what's happening in the current quarter on those pieces. Refer for everybody over to 10-Qs and 10-Ks for all of those pieces. But our Q3, we saw a nearly $49 million quarter, about a 53% growth year-over-year, slightly down over the prior quarter on those pieces, but about almost $144 million in sales for the first nine months of the year. So we're really happy with that. But I think the bigger part of what happened in Q3 was really about the expansion.
Because our first label that we have is the smallest part of bladder cancer, CIS plus or minus, and end of October, plus or minus, is when we actually received, and we are the first in the world to actually receive this, or first in the U.S. to receive this. We now have the entire BCG-unresponsive, so CIS plus and minus papillary alone. That is really a very important piece because if you look at that, it is somewhere between two to three or four times larger market, but more important than what the market size is what it does for the doctors.
I will tell you, the day that we got that approval, and probably over the couple of days that we got that approval, I probably had, I do not know, 20 physicians that would just call me personally, say, "Congratulations." They almost all said the same thing, "Finally, I can get back to treating my patients the way I see them. I have high-risk patients that are either BCG-naive, or I have high-risk patients that are BCG-unresponsive.
This nonsense about this CIS plus and minus, it just makes our billing office and our life miserable through those." They would usually go on to say, "NCCN is cool, but it does not actually address what payers really want is they want the FDA approval, so congratulations, and you have made our life a lot easier now." So we are really excited about that and happy to say that actually it is the second country that we got that in because the Emirates had previously approved it just prior to that with the full responsiveness on those. Beyond that, what is happening now and what happened in the last quarter as well was that we finished and met the endpoint that we reported out for our BCG-naive. So in high risk, you have got the unresponsive space, and you have got the BCG-naive.
Kind of think of them as frontline, second line, if you make it simple. Having met the endpoint for the naive trial means, and we have been working on this in parallel because you do not write one of these in a day, there are 700 or 800,000 pages, we will submit our sBLA for BCG-naive yet this year. So the team has really been going deep on that one, and we can go further into that in a little bit. I think those are some of the things I would kind of start to talk about and focus everybody in on.
Yeah, totally. Thanks, Rich. Maybe just on the 3Q earning, I believe, obviously, it's a very good number for nine months, year-on-year growth.
Yeah Then as you start to launch ANKTIVA.
But that's the first time a quarterly drawdown. So what's the reason, and how concerned people should be, right? So maybe any comments you have there.
Thank you. The way I would look at it is, as we've always said on this one here is, and it's really important to put things in context, the CIS plus or minus piece is a very small market. And there's a certain point when you're going to kind of run up against the headroom of that one. And what we've always said is we have to get out of the CIS-only market, and we got to get into that full BCG unresponsive market. So it was fortuitous that they gave it to us three months early, some would argue 10 months later than what we wanted it, because we wanted it prior on those pieces. But it's really important because that now gives us even more room to continue to grow inside of those.
Obviously, you've got more people in there, you've got competition in there, you've got BCG that we're working through, and we can talk a little bit about that.
Yep. But I think that's the way of looking at it, is that the positive news of all of those pieces is that the market just got bigger for us, and right now we're alone in that pack.
Excellent. That's literally my next question- Yeah in terms of the papillary-only population.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
